Lista de obras - Jun Wang - Dominio Público Uruguay

"Click" synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases

artículo científico publicado en 2006

2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel.

artículo científico publicado en 2014

3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.

artículo científico publicado en 2013

A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68

artículo científico publicado en 2019

Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays

artículo científico publicado en 2006

Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited

artículo científico publicado en 2017

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

artículo científico publicado en 2017

An assay suitable for high throughput screening of anti-influenza drugs

artículo científico publicado en 2013

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

artículo científico publicado en 2020

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

artículo científico publicado en 2020

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.

artículo científico publicado en 2017

De novo design of self-assembling foldamers that inhibit heparin-protein interactions

artículo científico publicado en 2014

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

artículo científico publicado en 2009

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

artículo científico publicado en 2024

Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling

artículo científico publicado en 2012

Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses

scientific article published on 11 June 2018

Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay

scientific article published on 21 November 2019

Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)

artículo científico publicado en 2019

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

artículo científico publicado en 2021

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

scientific article published on 13 September 2020

Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance

artículo científico publicado en 2016

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

artículo científico publicado en 2017

Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus

artículo científico publicado en 2013

Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus

artículo científico publicado en 2009

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

artículo científico publicado en 2022

Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.

artículo científico publicado en 2013

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

artículo científico publicado en 2020

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors

artículo científico publicado en 2020

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

artículo científico publicado en 2021

Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction

artículo científico publicado en 2017

Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel ⬇️

artículo científico publicado el 12 de agosto de 2011

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

artículo científico publicado en 2018

Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus

artículo científico publicado en 2011

Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus

artículo científico

Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.

artículo científico publicado en 2014

Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development

article

Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses.

artículo científico publicado en 2017

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

scientific article published on 28 March 2019

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.

artículo científico publicado en 2018

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.

artículo científico publicado en 2017

Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission.

artículo científico publicado en 2013

Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library

artículo científico publicado en 2007

Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters

artículo científico publicado en 2018

Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay

artículo científico publicado en 2013

Inhibitors targeting the influenza virus hemagglutinin.

artículo científico publicado en 2015

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

artículo científico publicado en 2022

Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

artículo científico publicado en 2016

Photoinduced Electron Transfer and Fluorophore Motion as a Probe of the Conformational Dynamics of Membrane Proteins: Application to the Influenza A M2 Proton Channel ⬇️

artículo científico publicado el 14 de marzo de 2011

Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.

artículo científico publicado en 2018

Protein and small molecule microarrays: powerful tools for high-throughput proteomics

artículo científico publicado en 2005

Proton and cation transport activity of the M2 proton channel from influenza A virus

artículo científico publicado en 2010

Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR.

artículo científico publicado en 2017

Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays

artículo científico publicado en 2007

Rapid assembly of matrix metalloprotease inhibitors using click chemistry.

artículo científico publicado en 2006

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

artículo científico publicado en 2021

Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.

artículo científico publicado en 2015

Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus

artículo científico publicado en 2017

Solid-State NMR Investigation of the Conformation, Proton Conduction, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel

artículo científico publicado en 2016

Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity

artículo científico publicado en 2009

Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy

artículo científico publicado en 2011

Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.

scientific article published on 17 January 2011

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

artículo científico publicado en 2020

Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus

artículo científico publicado en 2013

Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers

artículo científico publicado en 2010

Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.

artículo científico publicado en 2018

The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers

scientific article published on 07 June 2019

The antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

artículo científico publicado en 2021

Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

artículo científico publicado en 2018

Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor

scientific article published on 21 March 2019

X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case

scientific article published on 11 July 2019

X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance

artículo científico publicado en 2020

Lista de obras de Jun Wang

"Click" synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases

2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel.

3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.

A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68

Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays

Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses

An assay suitable for high throughput screening of anti-influenza drugs

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.

De novo design of self-assembling foldamers that inhibit heparin-protein interactions

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling

Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses

Discovery of Influenza Polymerase PA-PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay

Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus

Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction

Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel ⬇️

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus

Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus

Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.

Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development

Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses.

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.

Influenza virus A M2 protein generates negative Gaussian membrane curvature necessary for budding and scission.

Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library

Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters

Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay

Inhibitors targeting the influenza virus hemagglutinin.

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

Photoinduced Electron Transfer and Fluorophore Motion as a Probe of the Conformational Dynamics of Membrane Proteins: Application to the Influenza A M2 Proton Channel ⬇️

Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.

Protein and small molecule microarrays: powerful tools for high-throughput proteomics

Proton and cation transport activity of the M2 proton channel from influenza A virus

Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR.

Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays

Rapid assembly of matrix metalloprotease inhibitors using click chemistry.

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses.

Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus

Solid-State NMR Investigation of the Conformation, Proton Conduction, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel

Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity

Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy

Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus

Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers

Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.

The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers

The antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants.

Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor

X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case

X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance